Stock Traders Buy High Volume of Hims & Hers Health Call Options (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) was the target of unusually large options trading on Monday. Stock investors purchased 52,280 call options on the company. This represents an increase of approximately 58% compared to the typical volume of 33,036 call options.

Hims & Hers Health Stock Performance

NYSE:HIMS traded up $0.26 on Monday, reaching $17.84. The company’s stock had a trading volume of 21,820,662 shares, compared to its average volume of 7,701,318. Hims & Hers Health has a 1-year low of $5.65 and a 1-year high of $25.74. The firm has a market cap of $3.83 billion, a PE ratio of -1,758.00 and a beta of 1.08. The business’s 50-day moving average price is $21.37 and its two-hundred day moving average price is $15.74.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company had revenue of $278.20 million during the quarter, compared to analysts’ expectations of $270.37 million. During the same period in the prior year, the firm earned ($0.05) earnings per share. Hims & Hers Health’s revenue for the quarter was up 45.8% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health will post 0.2 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,000 shares of the firm’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $13.00, for a total transaction of $130,000.00. Following the completion of the transaction, the insider now directly owns 173,880 shares of the company’s stock, valued at approximately $2,260,440. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Soleil Boughton sold 2,503 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $12.33, for a total value of $30,861.99. Following the transaction, the insider now directly owns 159,357 shares of the company’s stock, valued at approximately $1,964,871.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Patrick Harrison Carroll sold 10,000 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $13.00, for a total value of $130,000.00. Following the sale, the insider now directly owns 173,880 shares in the company, valued at approximately $2,260,440. The disclosure for this sale can be found here. In the last quarter, insiders sold 782,901 shares of company stock worth $16,138,997. 17.71% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently made changes to their positions in HIMS. Vanguard Group Inc. grew its stake in shares of Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after buying an additional 136,907 shares during the period. Forerunner Ventures Management LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $86,836,000. Dimensional Fund Advisors LP grew its stake in shares of Hims & Hers Health by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after buying an additional 193,507 shares during the period. Farallon Capital Management LLC grew its stake in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after buying an additional 1,634,000 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Hims & Hers Health by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock valued at $11,523,000 after buying an additional 22,009 shares during the period. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Jefferies Financial Group boosted their price target on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, June 27th. Canaccord Genuity Group boosted their price target on Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, May 22nd. Bank of America boosted their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Canaccord Genuity Group assumed coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, TD Cowen boosted their price target on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Seven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and an average price target of $19.07.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.